1178, either, cat: 25
ALISKIREN ALONE OR IN COMBINATION WITH
HYDROCHLOROTHIAZIDE IN PATIENTS WITH THE LOWER RANGES
OF STAGE 2 HYPERTENSION: THE ACQUIRE RANDOMIZED, DOUBLEBLIND STUDY
H.R. Black1, F.A. Aguirre Palacios 2, M. Bijarnia3, A.K. Laflamme4, F. Baschiera5
1
New York University School of Medicine, New York, NY, USA, 2Hospital Militar
de Guayaquil HD-II-DE "Libertad", Guayaquil, Guayas, Ecuador, 3University
Duisburg–Essen, University Hospital Essen, Essen, Germany, 4Novartis Healthcare
Pvt Ltd, Madhapur/Hyderabad, India, 5Novartis Pharma AG, Basel, Switzerland
Patients with stage 2 hypertension (SBP ≥ 160 mm Hg and/or DBP
≥100 mm Hg) are at high cardiovascular risk and require intensive BPlowering therapy. This randomized, double-blind study is the first prospective trial
designed specifically to evaluate the direct renin inhibitor aliskiren, in patients with a
mean sitting SBP &#8805; 160 and <180 mm Hg (the lower ranges of stage 2 systolic
hypertension). After a 2–4-week washout, 688 patients were randomized to once-daily
aliskiren/hydrochlorothiazide (HCT) 150/12.5 mg or aliskiren 150 mg for 1 week, and
then double the doses for 11 weeks. Baseline BP was 167.1/95.0 mm Hg. At week 12,
both aliskiren/HCT and aliskiren provided substantial BP reductions from baseline
(30.0/12.6 and 20.3/8.2 mm Hg, respectively). Similar BP reductions were seen in the
subgroups of patients with isolated systolic hypertension and obesity.
In conclusion, aliskiren, with or without HCT, provides clinically significant BP
reductions and may therefore be an effective treatment option in patients with stage 2
hypertension.